Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KMT2A | Q03164 | 5/20 | 0.50 |
| ▸ | KDM4E | B2RXH2 | 4/20 | 0.50 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.50 |
| ▸ | MEN1 | O00255 | 4/20 | 0.50 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.50 |
| ▸ | GAA | P10253 | 1/20 | 0.48 |
| ▸ | MAP2K1 | Q02750 | 1/20 | 0.47 |
| ▸ | HPGD | P15428 | 1/20 | 0.45 |
| ▸ | PKM | P14618 | 1/20 | 0.45 |
| ▸ | CYP19A1 | P11511 | 1/20 | 0.44 |
| ▸ | STS | P08842 | 1/20 | 0.43 |
| ▸ | ACLY | P53396 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2246527 | 0.89 | MAP2K1 (0.53) | KMT2AKDM4EALDH1A1MEN1SMN1; SMN2 | |
| SCHEMBL972629 | 0.79 | ALDH1A1 (0.57) | KMT2AKDM4EALDH1A1MEN1SMN1; SMN2 | |
| SCHEMBL972176 | 0.77 | ALDH1A1 (0.78) | KMT2AKDM4EALDH1A1MEN1SMN1; SMN2 | |
| SCHEMBL970525 | 0.75 | ALDH1A1 (0.51) | KMT2AKDM4EALDH1A1MEN1SMN1; SMN2 | |
| SCHEMBL972170 | 0.69 | MAP2K1 (0.59) | KMT2AKDM4EALDH1A1MEN1SMN1; SMN2 | |
| SCHEMBL2245213 | 0.67 | MAP2K1 (0.62) | KMT2AKDM4EALDH1A1MEN1SMN1; SMN2 | |
| SCHEMBL972893 | 0.66 | KDM4E (0.55) | KMT2AKDM4EALDH1A1MEN1SMN1; SMN2 | |
| SCHEMBL970190 | 0.66 | MAP2K1 (0.70) | KMT2AKDM4EALDH1A1MEN1SMN1; SMN2 | |
| SCHEMBL2247578 | 0.65 | MAP2K1 (0.81) | KMT2AKDM4EALDH1A1MEN1SMN1; SMN2 | |
| SCHEMBL26434307 | 0.65 | ALDH1A1 (0.84) | KMT2AKDM4EALDH1A1MEN1SMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7872142-B2 | Coumarin derivatives useful as TNFα inhibitors | CHUGAI SEIYAKU KABUSHIKI KAISHA (JP) | 2011-01-18 | — | — | US | disclosed |
| US-20100174076-A1 | COUMARIN DERIVATIVES USEFUL AS TNF ALPHA INHIBITORS | CHUGAI SEIYAKU KABUSHIKI KAISHA (JP) | 2010-07-08 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100174076-A1 | COUMARIN DERIVATIVES USEFUL AS TNF ALPHA INHIBITORS | TNF, NFKBIA, TNFRSF1A | KMT2A 4821/4885KDM4E 4508/4885ALDH1A1 1402/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.